Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab – An attention may be required

Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab – An attention may be required

Background: C-reactive protein (CRP) is a marker of inflammation and infection. The main proinflammatory cytokine that leads to CRP gene expression is IL-6. The study aimed to compare CRP level between patients who were treated with Tocilizumab (TCZ), an il-6 receptor blocker, and other advanced ant...

Full description

Bibliographic Details
Main Authors: Mark Berman, Shlomo Berliner, Nancy Bashouti, Ori Elkayam, Tomer Ziv-Baran
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Heliyon
Subjects:
Tocilizumab
Infection
Rheumatoid arthritis
C-Reactive protein
Inflammation
Admission
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023038720

Similar Items

Similar Items